依维莫司洗脱支架与旁路移植术治疗左主干冠状动脉疾病
EXCEL试验将1905例左主干冠状动脉疾病且解剖复杂度低或中等(SYNTAX评分≤32)的患者随机分为依维莫司洗脱支架PCI组(948例)或CABG组(957例)。主要终点为3年全因死亡、卒中或心肌梗死的复合终点,非劣效界值为4.2个百分点。3年时PCI组主要终点事件率为15.4%,CABG组为14.7%(差异0.7个百分点,97.5%置信上限4.0个百分点,非劣效P=0.02;HR 1.00,95%CI 0.79-1.26)。30天死亡、卒中或心梗复合终点PCI组为4.9%,CABG组为7.9%(非劣效P<0.001,优效性P=0.008)。
要点
- 入选标准为左主干冠状动脉疾病且解剖复杂度低或中等,即SYNTAX评分≤32(由各中心评估)。
- 3年死亡、卒中或心梗复合终点:PCI组15.4% vs CABG组14.7%,差异0.7个百分点(97.5%置信上限4.0个百分点),非劣效P=0.02。
- 30天死亡、卒中或心梗复合终点:PCI组4.9% vs CABG组7.9%,非劣效P<0.001,优效性P=0.008。
- 3年死亡、卒中、心梗或缺血驱动血运重建复合终点:PCI组23.1% vs CABG组19.1%,非劣效P=0.01,优效性P=0.10。
- 依维莫司洗脱支架为氟聚合物涂层钴铬合金支架,PCI组948例,CABG组957例。
适用人群与场景
- 左主干冠状动脉疾病且解剖复杂度低或中等(SYNTAX评分≤32,由各中心评估)的 eligible 患者,共1905例随机分组。
诊断标准与关键阈值
- 解剖复杂度由各中心评估,以SYNTAX评分≤32定义为低或中等复杂度;SYNTAX评分为冠状动脉血管造影综合评估,最低分0分,分数越高(无上限)表示解剖越复杂。
处置流程与药物剂量
- PCI组:置入氟聚合物涂层钴铬合金依维莫司洗脱支架(948例)。
- CABG组:行冠状动脉旁路移植术(957例)。
研究设计与关键结果
- 随机对照试验,1905例左主干冠状动脉疾病患者随机分为PCI组(948例)或CABG组(957例)。
- 主要终点为3年全因死亡、卒中或心肌梗死复合终点,非劣效界值4.2个百分点;PCI组15.4% vs CABG组14.7%,差异0.7个百分点(97.5%置信上限4.0个百分点),非劣效P=0.02;HR 1.00(95%CI 0.79-1.26),优效性P=0.98。
- 30天死亡、卒中或心肌梗死复合终点:PCI组4.9% vs CABG组7.9%,非劣效P<0.001,优效性P=0.008。
- 3年死亡、卒中、心肌梗死或缺血驱动血运重建复合终点:PCI组23.1% vs CABG组19.1%,非劣效P=0.01,优效性P=0.10。
- 事件率基于Kaplan-Meier估计的首次事件时间分析。
证据类型、等级与局限
- 证据类型:随机对照试验(EXCEL,ClinicalTrials.gov NCT01205776),由Abbott Vascular资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于左主干冠状动脉疾病且SYNTAX评分≤32(由各中心评估)的患者,依维莫司洗脱支架PCI在3年死亡、卒中或心梗复合终点上不劣于CABG,30天事件率PCI组更低。
- 原文结论未据此给出推荐。
指南或共识出处
- EXCEL试验(ClinicalTrials.gov NCT01205776),发表于N Engl J Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with obstructive left main coronary artery disease are usually treated with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug-eluting stents may be an acceptable alternative to CABG in selected patients with left main coronary disease.
METHODS: We randomly assigned 1905 eligible patients with left main coronary artery disease of low or intermediate anatomical complexity to undergo either percutaneous coronary intervention (PCI) with fluoropolymer-based cobalt-chromium everolimus-eluting stents (PCI group, 948 patients) or CABG (CABG group, 957 patients). Anatomic complexity was assessed at the sites and defined by a Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score of 32 or lower (the SYNTAX score reflects a comprehensive angiographic assessment of the coronary vasculature, with 0 as the lowest score and higher scores [no upper limit] indicating more complex coronary anatomy). The primary end point was the rate of a composite of death from any cause, stroke, or myocardial infarction at 3 years, and the trial was powered for noninferiority testing of the primary end point (noninferiority margin, 4.2 percentage points). Major secondary end points included the rate of a composite of death from any cause, stroke, or myocardial infarction at 30 days and the rate of a composite of death, stroke, myocardial infarction, or ischemia-driven revascularization at 3 years. Event rates were based on Kaplan-Meier estimates in time-to-first-event analyses.
RESULTS: At 3 years, a primary end-point event had occurred in 15.4% of the patients in the PCI group and in 14.7% of the patients in the CABG group (difference, 0.7 percentage points; upper 97.5% confidence limit, 4.0 percentage points; P=0.02 for noninferiority; hazard ratio, 1.00; 95% confidence interval, 0.79 to 1.26; P=0.98 for superiority). The secondary end-point event of death, stroke, or myocardial infarction at 30 days occurred in 4.9% of the patients in the PCI group and in 7.9% in the CABG group (P<0.001 for noninferiority, P=0.008 for superiority). The secondary end-point event of death, stroke, myocardial infarction, or ischemia-driven revascularization at 3 years occurred in 23.1% of the patients in the PCI group and in 19.1% in the CABG group (P=0.01 for noninferiority, P=0.10 for superiority).
CONCLUSIONS: In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years. (Funded by Abbott Vascular; EXCEL ClinicalTrials.gov number, NCT01205776 .).
参考来源
- Stone GW, Sabik JF, Serruys PW, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med. 2016. PMID: 27797291
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。